Review: management of Parkinson’s disease

David J Pedrosa
Lars Timmermann
Department of Neurology, University Hospital Cologne, Cologne, Germany

Abstract: Parkinson’s disease (PD) is one of the most frequent neurological diseases. Despite the modern imaging and nuclear techniques which help to diagnose it in a very early stage and lead to a better discrimination of similar diseases, PD has remained a clinical diagnosis. The increasing number of available treatment options makes the disease management often complicated even when the presence of PD seems undoubted. In addition, nonmotor symptoms and side effects of some therapies constitute some pitfalls already in the preclinical state or at the beginnings of the disease, especially with the progressive effect on patients. Therefore, this review aimed to summarize study results and depict recommended medical treatments for the most common motor and nonmotor symptoms in PD. Additionally, emerging new therapeutic options such as continuous pump therapies, eg, with apomorphine or parenteral levodopa, or the implantation of electrodes for deep brain stimulation were also considered.

Keywords: Parkinson’s disease, disease management, side effects, nonmotor symptoms, DBS, pump therapies

Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder, initially characterized by a loss of dopaminergic neurons in the substantia nigra that spreads over the course of the disease to almost the whole central nervous system. But although the first description of the “shaking palsy” by James Parkinson was published almost 200 years ago, there is still a lack of understanding of the causes of PD. However, great insight into the pathomechanisms was gained during the last decades, identifying in microscopic postmortem studies ubiquitous Lewy bodies as histological correlates of cell death.1

Nevertheless, PD remains a clinical diagnosis with cardinal motor symptoms such as akinesia, rigidity, and tremor. Yet, advances in different imaging techniques, such as functional magnetic resonance imaging or nuclear imaging techniques, provide supplementary information allowing a precise distinction from differential diagnosis, such as essential tremor or other parkinsonian syndromes.2,3 Additionally, they allow a classification of subtypes, allowing a more accurate and even earlier diagnosis.4,5 This is crucial for avoiding a delayed therapy for evolving symptoms and therefore improving quality of life (QOL). Also, it could offer in the near future the possibility of designing and studying disease modifying drugs able to slow neurodegeneration, and tailoring patient-specific therapy strategies. One possible way might be the development of alternative and more invasive options that have emerged recently, such as pump therapies or deep brain stimulation (DBS). All these treatments have shown promising results in terms of reducing motor symptoms (tremor, akinesia, and/or rigidity).
Nonmotor symptoms have also gained importance, as patients report them impairing their daily life. For physicians, however, they appear at times difficult to treat and even to identify, as they often intermingle with comorbidities. In this respect, many results have been published lately concerning different medical agents and their efficacy and possibilities, but also their restrictions in PD management. Therefore, this review aims to summarize current recommendations and therapeutic strategies for PD patients.

**Nonpharmacologic therapies**
From clinical experience and by what patients report, exercise, physical therapy, and speech and/or occupational therapy have a sustainable effect for PD patients in terms of maintaining the status quo and improving QOL. For this purpose, there are numerous offered approaches; yet, listing all of them would certainly go beyond the scope of this work. Still, only a few methods have been tested in high-standard studies and constitute effective therapies.

Methods considered helpful include multiple forms of physical exercise such as tai chi or LSVT BIG™ (LVST Global, Inc, Tucson, AZ, USA) but also speech therapy with the Lee Silverman Voice Treatment. Nevertheless, they can hardly be considered a replacement of pharmaceuticals, but rather a basis which has to be extended by medical treatment. Particularly, patients suffering from axial signs such as freezing of gait, camptocormia, or severe gait and speech problems do benefit from regular physical and/or speech therapy, and attention can be drawn to movement strategy training or cueing. All other PD patients should also receive regular physical and/or speech therapy and should be motivated to regular exercise. In agreement with other authors, well-designed trials are needed to demonstrate efficient but also cost-effective approaches for nonpharmacological therapies in PD.

**Medical treatment of PD**
Therapy should be started as soon as the diagnosis of PD is made. A delayed start of the treatment cannot be justified with the risk of motor fluctuations and one has to keep in mind that patients show the best results when treated early. In addition, the authors believe that the mere attendance of a professional is a consequence of a decreased QOL and therefore an indication for therapy. However, the numerous available possibilities make the best choice difficult for the different indications.

**Disease modification**
One of the foci in recent PD research has addressed pathomechanisms in an early state for hampering disease progression. This deceleration of the progress in PD has been demonstrated in animal models with selegiline, rasagiline, pramipexole, and coenzyme Q10. To date, however, few results were reproducible in humans. Thus, 1 mg rasagiline daily over 18 months possibly delays clinical progression in early stages of PD. This is why it is still considered – despite being inconclusive with prior studies – a good choice for younger patients with only mild symptoms. These patients not only benefit from the possible disease modification but also from the improvement in motor symptoms. When rasagiline is not sufficient, it can also be safely combined with other agents, eg, dopamine agonists (DA). In contrast, studies investigating the latter ones alone (eg, pramipexole) did not show conclusive neuroprotective properties and can therefore not be recommended for this purpose.

Further insight into disease modification and current investigation can be found in the review by Hart et al. The properties of rasagiline as a possibly disease modifying drug can be found in Table 1.

**Management of motor symptoms (eg, akinesia, rigidity, and tremor)**

**Dopaminergic medication**

**Levodopa**
Levodopa in combination with a peripheral decarboxylase inhibitor is still the most effective medication available. Oral application of levodopa is available in different galenic formulations. The wide range of possibilities allows a selective choice if either fast delivery is needed (eg, in the morning) or long-lasting effects are desired (eg, during the night). Alternatively, “on” phases might be prolonged when using combinations such as catechol-O-methyltransferase (COMT) inhibitors with levodopa. However, patients treated with levodopa tend to develop motor complications after 4–6 years. Complications after long-term levodopa treatment involve medically refractory fluctuations and/or dyskinesias. Therefore, the primary use of levodopa should only be considered when there is a lack of efficiency with DAs or side effects impede sufficient symptom control in younger patients with agents other than levodopa. In contrast, levodopa is recommended in older patients as monotherapy or in combination with other drugs even as the first-line option, as it shows high efficacy and good safety.

**DAs**
This group of pharmaceuticals comprises medications that activate the dopaminergic receptor with an individual affinity
Table 1 Possible disease modifying agents in the treatment of Parkinson’s disease

| Substance | Mechanism | Dosage | Adverse events | Special monitoring | Evidence |
|-----------|-----------|--------|----------------|--------------------|----------|
| MAO<sub>B</sub> inhibitors | Selective inhibition of MAO<sub>B</sub> Æ less metabolization of monoamines including dopamine | 1 mg/day | Nausea, dizziness, abdominal pain, dry mouth, vivid dreams, and/or hallucinations, dyskinesias, might improve tremor at the beginning | None required but possibility of inducing serotonin syndrome effect together with SSRi, for example, is feasible (although improbable) | Possibly delays progression in early stages of the disease, but at present insufficient evidence for a role in prevention/delay of PD<sup>28</sup> |

Abbreviations: MAO<sub>B</sub>, monoamine oxidase B; PD, Parkinson’s disease; SSRi, selective serotonin reuptake inhibitor.

...to the distinct subtypes of it (pharmacokinetic properties and details can be found in Kvernmo et al.<sup>27</sup>) In general, there are two different groups: (1) ergoline and (2) nonergoline derivates. The former are not recommended as first-line medications anymore since they can produce several severe side effects which may cause a considerable risk if they are not specially monitored.<sup>28</sup> The nonergoline DA, in contrast, are considered efficacious and safe and are therefore especially recommended for treatment in younger patients in combination with levodopa or as a monotherapy.<sup>28</sup> Therefore, a wide range of agents and galenic formulations allows individual therapy, providing constant levels of medication and, eventually, good motor control. In addition, motor complications due to long-term treatment are not as likely as with levodopa therapy and can even be reduced by treatment with DA.<sup>28-31</sup> Nevertheless, it should be noted that DAs have a worse short-term risk profile compared to levodopa, causing more psychiatric and nonmotor side effects and making regular follow-up necessary.

Other drugs
Besides levodopa and DAs, there are other medications which have proven efficacious for treatment of motor symptoms in PD.<sup>28</sup> These drugs improve the plasmatic levels of levodopa and/or dopamine (monoamine oxidase B [MAO<sub>B</sub>] inhibitors or COMT inhibitors). Due to their distinct mechanisms, however, each of these substances has advantages and properties that need to be considered. COMT inhibitors, for instance, have no intrinsic effect but increase plasmatic levels of levodopa. It has been proven efficacious for adjunct therapy with levodopa and for the treatment of motor fluctuations.<sup>28</sup> Still, there are side effects to be considered, especially tolcapone leading to hepatotoxicity.<sup>32</sup> Therefore, entacapone – particularly combined with levodopa – is widely applied in clinical practice, improving activities of daily living and reducing the “off” time<sup>25</sup> in fluctuating patients.<sup>33</sup> Similar characteristics can be found for MAO<sub>B</sub> inhibitors as they also provide higher levels of dopamine, decelerating its metabolization. Hence, it is effective as monotherapy for motor symptoms and also as an adjunct to levodopa.<sup>28</sup> Additionally, both available medications (selegiline and rasagiline) are recommended due to their good safety. Taken together, the symptoms of PD might also be positively influenced, targeting the metabolization of dopamine.

On the other hand, neurotransmitters other than dopamine have also shown efficacy for the treatment of PD. Amantadine, for instance, possibly works by antagonizing N-methyl-D-aspartic acid receptors. However, the role is not clear and interference with other neurotransmitters is also feasible. Despite its unclear mechanism of action, it is recommended for therapy of motor symptoms in young patients<sup>28</sup> and appears to be useful in decreasing levodopa-induced dyskinesias<sup>34,35</sup> Other target structures, eg, the adenosine receptor, are currently under investigation and show promising results.<sup>36-38</sup> This should motivate the expansion of ongoing basic research in order to discover further ways for symptomatic treatments for PD.

A summary of the recommended treatment of motor symptoms in PD with the distinct pharmaceuticals can be found in Table 2.

Management of special motor symptoms

Dyskinesias and fluctuations
The underlying pathogenesis of dyskinesias and fluctuations is probably the iatrogenic discontinuous administration of dopamine, which is in contrast to the physiologic steady concentrations.<sup>39</sup> As a consequence, dyskinesias and fluctuations often emerge due to early and longstanding levodopa therapy. Thus, the best treatment is the delay of levodopa in favor of DA or drugs with other target structures.

If, however, fluctuations occur, a practical approach is to reduce levodopa intervals and keep the dosage constant or to increase it only slightly, being aware that...
### Table 2 Management of motor impairments in Parkinson’s disease

| Substance                          | Mechanism                                                                 | Dosage                                                                 | Adverse events                                      | Special monitoring                  | Evidence                                                                 |
|------------------------------------|---------------------------------------------------------------------------|------------------------------------------------------------------------|-----------------------------------------------------|-------------------------------------|--------------------------------------------------------------------------|
| **Dopaminergic medication**        |                                                                           |                                                                       |                                                     |                                     |                                                                          |
| Levodopa together with peripheral  | Precursor to dopamine                                                     | Depending on patient and the therapeutic effect, up to 1000–1500 mg/day | Hypotension, nausea, disorientation and confusion, insomnia and/or vivid dreams, hallucinations, somnolence | None required                      | Efficacious for symptomatic monotherapy and for the treatment of motor complications 
| aromatic acid decarboxylase        |                                                                           |                                                                       |                                                     |                                     |                                                                          |
| inhibitor in a standard formulation |                                                                           |                                                                       |                                                     |                                     |                                                                          |
| levodopa together with peripheral  | Precursor to dopamine                                                     | Depending on patient and the therapeutic effect, up to 1000–1500 mg/day | Hypotension, nausea, disorientation and confusion, insomnia and/or vivid dreams, hallucinations, somnolence | None required                      | Efficacious for symptomatic monotherapy but insufficient evidence for treatment of motor complications |
| aromatic acid decarboxylase inhibitor in a controlled release formulation |                                                                           |                                                                       |                                                     |                                     |                                                                          |
| Pramipexole                        | Partial or full dopamine receptor agonist with different affinity to the distinct dopamine receptor subtypes | 3 × 0.35–0.7 mg/day                                                   | Leg swelling, somnolence, fatigue, nausea, constipation and edema, impulsive or compulsive behavior | Psychiatric side effects should be taken into consideration and monitored cautiously | Efficacious for symptomatic monotherapy, symptomatic therapy adjunct to levodopa, the prevention/delay and the treatment of motor complications |
| Ropinirole                         | Partial or full dopamine receptor agonist with different affinity to the distinct dopamine receptor subtypes | 6–24 mg/day                                                           | Leg swelling, somnolence, fatigue, nausea, constipation and edema, impulsive or compulsive behavior | Psychiatric side effects should be taken into consideration and monitored cautiously | Efficacious for symptomatic monotherapy, symptomatic therapy adjunct to levodopa, the prevention/delay and the treatment of motor complications |
| Rotigotine                         | Partial or full dopamine receptor agonist with different affinity to the distinct dopamine receptor subtypes | Once-daily transdermal patch 4–16 mg/day                             | Local skin reactions, leg swelling, somnolence, fatigue, nausea, constipation and edema, impulsive or compulsive behavior | Skin reactions at the application site have to be considered. Psychiatric side effects should be taken into consideration and monitored cautiously | Efficacious for symptomatic monotherapy, symptomatic therapy adjunct to levodopa, the prevention/delay and the treatment of motor complications |
| Pirebdil                           | Partial or full dopamine receptor agonist with different affinity to the distinct dopamine receptor subtypes | 150–250 mg/day                                                        | Leg swelling, somnolence, fatigue, nausea, constipation and edema, impulsive or compulsive behavior | Psychiatric side effects should be taken into consideration and monitored cautiously | Efficacious for symptomatic monotherapy, symptomatic therapy adjunct to levodopa |
| **COMT inhibitors**                |                                                                           |                                                                       |                                                     |                                     |                                                                          |
| Entacapone                         | Reversible inhibition of COMT → less inactivation of levodopa/dopamine | Together with levodopa 300–1200 mg/day                               | Digestive symptoms such as diarrhea and/or nausea, orthostatic hypotension, urine discoloration | None required                      | Efficacious as symptomatic adjunct to levodopa in PD patients with motor fluctuations (but not in patients without motor fluctuations) as first-line option |
| Tolcapone                          | Reversible inhibition of COMT → less inactivation of levodopa/dopamine | Together with levodopa 300–600 mg/day                                | Hepatotoxicity, digestive symptoms such as diarrhea and/or nausea, orthostatic hypotension, urine discoloration | Regular follow-up and control of liver transaminases required | Efficacious as symptomatic adjunct to levodopa in PD patients with motor fluctuations as second-line option (after entacapone) |
Selegiline
Selective inhibition of MAO-B → less metabolization of monoamines including dopamine
1–2 × 5 mg/day
Nausea, dizziness, abdominal pain, dry mouth, vivid dreams and/or hallucinations, dyskinesias, might improve tremor at the beginning
None required but possibility of inducing serotonin syndrome effect together with SSRi, for example, is feasible (although improbable)
Efficacious for symptomatic monotherapy, symptomatic adjunct to levodopa, treatment of motor complications

Rasagiline
Selective inhibition of MAO-B → less metabolization of monoamines including dopamine
1 mg/day
Nausea, dizziness, abdominal pain, dry mouth, vivid dreams and/or hallucinations, dyskinesias, might improve tremor at the beginning
None required but possibility of inducing serotonin syndrome effect together with SSRi, for example, is feasible (although improbable)
Efficacious for symptomatic monotherapy, symptomatic adjunct to levodopa, treatment of motor complications

Other drugs
Amanadine
Unclear, possibly the interaction of several pharmacological mechanisms
2–3 × 100–200 mg/day
Reversible corneal edema, nervousness, anxiety, agitation, insomnia, exacerbations of preexisting seizure disorders and psychiatric symptoms
None required
Likely efficacious for symptomatic monotherapy, symptomatic adjunct to levodopa, treatment of motor complications

Abbreviations: COMT, catechol-O-methyltransferase; MAO-B, monoamine oxidase B; PD, Parkinson's disease; SSRi, selective serotonin reuptake inhibitor.
lacks efficiency for therapy of these symptoms.\textsuperscript{45} However, when tremor is the dominant source of disability, thalamic DBS still constitutes a feasible and very efficacious therapy option in refractory tremor or when contraindications against medical treatment are present.

**Axial motor signs**

Axial motor signs entail symptoms which affect the patient’s axis and therefore have no lateral preference (eg, akinesia, tremor). Treatment of axial motor signs is particularly challenging since there is often no good response on classical parkinsonian medication or STN-DBS.\textsuperscript{146–47} This disparity might be attributable to different pathomechanisms, as non-dopaminergic neurotransmitters have been postulated to play a crucial role in the emergence of freezing of gait (FoG) or camptocormia – two of the most frequent axial motor signs.

**FoG**

FoG is a paroxysmal phenomenon, most commonly found in patients with advanced PD; however, freezing behavior can also affect speech and the upper limbs. The underlying pathophysiology remains uncertain, causing difficulties for identifying a concrete medical or surgical target. Physical therapy and speech therapy and rehabilitation approaches for FoG are highly effective and should therefore be recommended. Several studies have been published recently which show attentional strategies and cueing being useful\textsuperscript{48–50} and highly effective to overcome FoG.\textsuperscript{51,52} Other rehabilitative strategies address exercise in groups\textsuperscript{53} and treadmill training, and can also be recommended to patients suffering from FoG. This can be regarded independently from possible surgical or medical treatments.

The medical therapy of FoG requires a differentiation between freezing during “on” or “off” periods in the first instance. The “on” freezing can be treated by reducing medication. The “off” freezing, on the other hand, is more common and typically responds to treatments aimed at improving “on” time. Occasionally, however, levodopa deteriorates FoG and consequently it may be necessary to reduce dopaminergic medication. Furthermore, MAO\textsubscript{B} inhibitors have been associated with a decreased likelihood of developing FoG. However, these agents rarely reduce freezing behavior once it has developed.\textsuperscript{54} The contradictory role of dopamine in FoG is clarified by studies that have shown that patients suffer more often from FoG when receiving DA than those treated with placebo,\textsuperscript{55} yet withdrawing DA rarely improves FoG. Hence, nondopaminergic targets and drugs have been investigated including amantadine, selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, methylphenidate, and botulinum toxin injections in leg muscles. Although these studies have shown promising results, a solid recommendation is still impossible as the studies were small and uncontrolled (for further review see Giladi).\textsuperscript{56} The difficulty in finding effective relief for freezing behavior has also led to the investigation of therapies besides medical treatment.

The surgical therapy options for FoG such as DBS might be beneficial, although results are highly controversial. Particularly forms appearing in the “off” time might be treated with STN-DBS.\textsuperscript{57,58} At the same time, it has been reported that FoG is induced by STN-DBS.\textsuperscript{57} This situation becomes even more complicated as reducing the frequency of STN-DBS has also been reported to ameliorate FoG,\textsuperscript{59} and new target points such as the pedunculopontine nucleus are under investigation, with conflicting results.\textsuperscript{60} In summary, the efficacy of DBS for FoG requires further investigation. Currently, in the authors’ opinion, DBS should be considered for individual therapeutic attempts and when regular follow-up is possible for frequent changes in stimulation parameters. As previously mentioned, all surgical or medical therapy attempts should be supported by intensive physical and/or speech therapy.

**Camptocormia**

Camptocormia describes a severe flexion of the trunk, presenting in a sitting position but classically worsening when standing or walking. There are several possible theories explaining camptocormia, such as paraspinal myopathy, axial dystonia, or drug-induced forms. To date, however, there is no consistent pathophysiological concept available. This lack of understanding and few high-standard studies make all recommendations rely on empirical knowledge. The adjustment of dopaminergic therapy (controlled release levodopa therapy or levodopa with entacapone) has been reported to not only improve lateral symptoms but also camptocormia;\textsuperscript{51} other patients profit from the injection of botulinum toxin into rectal abdominal muscles, emphasizing a dystonic component in its genesis.\textsuperscript{62} In the authors’ own experience, however, patients describe physical exercise and the use of equipment such as walkers or rollators as helpful, especially when the handle bars are adjusted to a high position.

All presented results of the treatment of special motor restraints such as dyskinesias, tremor, or axial motor signs can be found in Table 3.

**Medical treatment of nonmotor symptoms in PD**

**Sleep disorders**

Different forms of sleep disorders can be detected among patients suffering PD and can also possibly indicate a
| Symptom/substance | Mechanism | Dosage | Adverse events | Special monitoring | Evidence |
|-------------------|-----------|--------|----------------|-------------------|----------|
| Dyskinesias        |           |        |                |                   |          |
| Pramipexole        | Partial or full dopamine receptor agonist with different affinity to the distinct dopamine receptor subtypes<sup>27</sup> | $3 \times 0.35–0.7$ mg/day | Leg swelling, somnolence, fatigue, nausea, constipation and edema, impulsive or compulsive behavior | Psychiatric side effects should be taken into consideration and monitored cautiously | Patients treated with pramipexole showed a significantly lower risk of motor complications in dyskinesias especially and wearing off<sup>30,40,140</sup> |
| Ropinirole         | Partial or full dopamine receptor agonist with different affinity to the distinct dopamine receptor subtypes<sup>27</sup> | 6–24 mg/day | Leg swelling, somnolence, fatigue, nausea, constipation and edema, impulsive or compulsive behavior | Psychiatric side effects should be taken into consideration and monitored cautiously | Patients treated with ropinirole (also with prolonged release formulation) showed a significantly lower risk of motor complications in dyskinesias especially and wearing off<sup>9,41,142</sup> |
| Amantadine         | Unclear, possibly the interaction of several pharmacological mechanisms | 2–3 $\times 100–200$ mg/day | Reversible corneal edema, nervousness, anxiety, agitation, insomnia, exacerbations of preexisting seizure disorders and psychiatric symptoms | None required | Clinically useful for treating levodopa-induced dyskinesias<sup>34,35,41,143</sup> |
| Clozapine          | Antagonist at the 5-HT<sub>2A</sub>, dopamine, and several other receptors | 25–50 mg/day | Agranulocytosis, cardiac toxicity, hypersalivation, fatigue, weight gain | Regular blood testing is mandatory and regular echocardiograms can be performed | Possibly useful in the treatment of levodopa-induced dyskinesias<sup>144</sup> |
| Tremor<sup>3</sup> |           |        |                |                   |          |
| Propranolol        | Antagonist at adrenoreceptors (sympatholytic) | $3 \times 80$ mg/day | Nausea, diarrhea, bronchospasms, exacerbation of Raynaud’s syndrome, bradycardia, hypotension, hallucinations, erectile dysfunction, sleep disturbances, alteration of glucose metabolism | None required | Possibly useful, particularly when there is postural tremor |
| Biperiden          | Antagonist at muscarinic M<sub>1</sub> receptors | 3–16 mg/day | Drowsiness, vertigo, agitation, anxiety, delirium, and confusion; additionally, peripheral side effects may be observed (eg, dry mouth, obtipation, and mydriasis) | None required | Efficacious for symptomatic monotherapy and symptomatic adjunct to levodopa for treating tremor<sup>145</sup> |
| Clozapine          | Antagonist at the 5-HT<sub>2A</sub>, dopamine, and several other receptors | 12.5–50 mg/day | Agranulocytosis, cardiac toxicity, hypersalivation, fatigue, weight gain | Regular blood testing is mandatory and regular echocardiograms can be performed | Treatment of levodopa-resistant tremor<sup>146</sup> |

Abbreviation: 5-HT<sub>2A</sub>, 5-hydroxytryptamine receptor 2A.

Clinical symptom. Rapid eye movement behavior disorder, for instance, shows a higher prevalence in PD and half of all rapid eye movement behavior disorder patients will develop PD, dementia with Lewy bodies, or multiple system atrophy within 10 years. Hence, α-synuclein pathology possibly starts decades before the first motor symptoms. Possible therapy of rapid eye movement behavior disorder consists in adding clonazepam (0.5–2.0 mg at night), which might reduce the symptoms significantly.<sup>64</sup>

Nevertheless, insomnia in PD is the most common sleep disorder. It involves difficulty with initiation, duration, and/or maintenance of sleep, and consequent daytime somnolence. In PD, and due to dopaminergic deficiency, levodopa in a controlled release formulation at night is possibly efficacious,
although there are controversial results. For DAs, there is a lack of controlled studies. Only pergolide should not be used; it improves sleep mildly but its use is accompanied by a considerable number of adverse events. Additionally, side effects of DAs especially, but also levodopa (eg, excessive daytime sleepiness, sudden onset of sleep), have a severe repercussion on QOL. This should be kept in mind when prescribing medication at first instance. Other drugs tested during recent years without direct effect on dopamine, such as eszopiclone or melatonin, did not show any conclusive results in terms of efficacy for treating insomnia and cannot be recommended.

Restless legs syndrome (RLS) can also be detected more frequently in PD patients. RLS leads to an irresistible urge to move the legs accompanied by uncomfortable sensations worsened at rest and exacerbated in the evening or at night. Therapy for RLS associated with PD is the same as in other forms and includes general measures such as maintaining a regular sleep pattern, moderate exercise, massaging the legs, and using heating pads or ice packs. Possible medications are levodopa, benzodiazepine, gabapentin, opioids, and pregabalin. DAs or gabapentin enacarbil as a first-line medical option show very good results. The former are particularly useful as they treat motor symptoms and RLS at the same time. In addition, it has been shown that in long-term treatment, some DAs cause less augmentation compared to levodopa. This phenomenon depicts worsening of RLS and the spread to previously unaffected parts of the body. DBS for treating RLS cannot be recommended as there are inconclusive results and some authors suspect manifestation after electrode implantation, possibly due to the reduction of dopaminergic therapy. Hence, the role of DBS for treatment in RLS remains elusive.

However, as STN-DBS provides regular dopaminergic stimulation and therefore improves nocturnal mobility and/or dystonic symptoms, it might be helpful for reducing unaise in PD patients. Apart from subjective improvement, there are also objective measurements showing better sleep quality. Therefore STN-DBS might be helpful, compared to thalamic high-frequency stimulation of the thalamus, which does not influence sleep.

Lastly, advice about sleep hygiene, treatment of concomitant depression, and the reduction of hypnosedative agents are all considered common sense measures. Medical interventions for improvement of sleep problems in PD are listed in Table 4.

Excessive daytime sleepiness
Patients treated with DA or levodopa often experience excessive daytime sleepiness and sudden onset of sleep as side effects. However, sleep disturbances and possible changes in daytime alertness were already described by James Parkinson and might therefore be a symptom of the disease itself. Medications aiming to reduce excessive daytime sleepiness are rare. Modafinil has been tested as a possible treatment, providing inconclusive results and therefore not recommended. It is important to keep in mind the rare dermal side effects (eg, Stevens–Johnson syndrome, drug rash with eosinophilia, systematic symptoms) and the risk of inducing mania, delusions, hallucinations, and/or aggression. In the authors’ opinion, the only possible advice so far is to reduce dopaminergic medication as far as needed and possibly switch to alternative medications as far as practicable.

Autonomic dysfunctions in PD
Autonomic dysfunction constitutes important constraints in the course of PD. The possible cause are Lewy bodies in brain areas involved in the control of vegetative functions, such as the hypothalamus or the dorsal vagus nucleus, but also in the spinal cord, sympathetic ganglia, and the plexus of the digestive tract. The most common autonomic symptoms are orthostatic dizziness, gastrointestinal problems, and bladder and erectile dysfunction.

Concerning orthostatic hypotension and dizziness, nonpharmacological interventions should be attempted first, such as sleeping in a head-up position, fragmentation of meals, avoidance of low sodium and carbohydrate-rich meals, increased water (2–2.5 L/day) and salt intake (>8 g or 150 mmol/L), or wearing support stockings. For medication, fludrocortisone and domperidone might have beneficial effects.

In contrast, urinary disturbances should be treated primarily with proper medications. These constraints are not only very frequent but also have a severe impact on QOL. Therapeutic options are an optimization of dopaminergic therapy, as this might improve storage properties in PD patients. However, study results are contradictory. An alternative might be the prescription of peripherally acting anticholinergics such as tropium chloride (10–20 mg two to three times daily) or oxybutynin (2.5–5 mg twice daily). Nevertheless, there are not enough high-standard studies to assure efficacy.

Other frequent autonomic dysfunctions are gastrointestinal motility problems in PD. Therapy constitutes different approaches: constipation can be treated with macrogol effectively, while nausea and/or vomiting in connection with the initial intake of levodopa can be antagonized by domperidone or ondasetron. Dysphagia in late stages of PD is also a very disabling and potentially harmful symptom, as malnutrition, dehydration, aspiration, or even asphyxia may occur. Management includes a sufficient dopaminergic therapy, injection of botulinum toxin, and different forms...
### Table 4 Treatment of sleep disorders in Parkinson’s disease patients

| Symptom/substance | Mechanism | Dosage | Adverse events | Special monitoring | Evidence |
|-------------------|-----------|--------|----------------|--------------------|----------|
| **REM sleep behavior disorder** | | | | | |
| Clonazepam | Benzodiazepine (allosteric modification of GABA<sub>A</sub> receptor) | 0.5–2.0 mg at night | Drowsiness, confusion, irritability and aggression and/or psychomotor agitation, cognitive impairments, hallucinations | None required | Possibly effective, but only case reports and retrospective studies available <sup>47,44</sup> |
| **Insomnia** | | | | | |
| Levodopa together with peripheral aromatic acid decarboxylase inhibitor in a controlled release formulation | Precursor to dopamine | 200 mg at night | Hypotension, nausea, disorientation and confusion, insomnia and/or vivid dreams hallucinations, somnolence | None required | Possibly effective for increasing sleep time and nocturnal akinesia <sup>40</sup> |
| **RLS** | | | | | |
| Pramipexole | Partial or full dopamine receptor agonist with different affinity to the distinct dopamine receptor subtypes<sup>27</sup> | 3 × 0.33–0.7 mg/day | Fatigue, nausea, constipation and edema, somnolence | Psychiatric side effects should be taken into consideration and monitored cautiously | Efficacious in the treatment of moderate-to-very severe RLS<sup>149–151</sup> and especially suited for PD |
| Ropinirole | Partial or full dopamine receptor agonist with different affinity to the distinct dopamine receptor subtypes<sup>27</sup> | 6–24 mg/day | Fatigue, nausea, constipation and edema, somnolence | Psychiatric side effects should be taken into consideration and monitored cautiously | Efficacious in the treatment of moderate-to-very severe RLS<sup>152,153</sup> and especially suited for PD |
| Rotigotine | Partial or full dopamine receptor agonist with different affinity to the distinct dopamine receptor subtypes<sup>27</sup> | Once-daily transdermal patch 4–16 mg/day | Fatigue, nausea, constipation and edema, somnolence | Skin reactions at the application site have to be considered. Psychiatric side effects should be taken into consideration and monitored cautiously | Rotigotine as a transdermal patch is effective in the treatment of moderate-to-severe RLS<sup>154,155</sup> and especially suited for PD |
| Gabapentin enacarbil | Prodrug of gabapentin (see below) | 600–1800 mg/day | Fatigue, dizziness, weight gain, edema, drowsiness | None required | Gabapentin enacarbil is effective in the treatment of moderate-to-severe RLS<sup>156–158</sup> but experience is lacking. Second-line option in PD |
| Levodopa together with peripheral aromatic acid decarboxylase inhibitor in a standard or controlled release formulation | Precursor to dopamine | 200–400 mg at night | Hypotension, nausea, disorientation and confusion, insomnia and/or vivid dreams hallucinations somnolence | None required | Levodopa is effective in the treatment of RLS, but carries the risk of augmentation<sup>161</sup> |
| Gabapentin | Possibly inactivates the α,δ-subunit of a voltage gated calcium-channel | 600–1800 mg/day | Fatigue, dizziness, weight gain, edema, drowsiness | None required | Gabapentin may be used as is it is effective in the treatment of mild-to-moderate RLS<sup>162,163</sup> but is considered second-line option due to possible side effects<sup>66</sup> |
| **Opioids** | Binding at different opioid receptors in the central and peripheral nervous system | Different agents available | Nausea and vomiting, drowsiness, dry mouth, myosis, constipation | Clinical monitoring of worsening of sleep apnea and potential of abuse | Opioids are effective in the treatment of RLS, especially for patients with RLS that is not relieved by other treatments<sup>66</sup> |

(Continued)
Table 4 (Continued)

| Symptom/substance | Mechanism | Dosage | Adverse events | Special monitoring | Evidence |
|-------------------|-----------|--------|----------------|-------------------|----------|
| Pregabalin        | Possibly inactivates the α3β subunit of a voltage-gated calcium channel | 50–450 mg/day | Dizziness, drowsiness, increased appetite, euphoria, confusion, vivid dreams, attention changes, tremor, dysarthria, dry mouth, constipation | None required | Pregabalin is effective in the treatment of moderate-to-severe RLS²⁴ |

Abbreviations: GABA, γ-aminobutyric acid type A; PD, Parkinson’s disease; REM, rapid eye movement; RLS, restless legs syndrome.

of rehabilitative treatments.⁸⁰ Enteral feeding options such as a short-term nasogastric feeding tube or long-term feeding system (percutaneous endoscopic gastrostomy) can be considered as a final option.

For erectile dysfunction, sildenafil or other phosphodiesterase type 5 inhibitors might be efficacious when considering side effects/contraindications and interactions with other medications.⁸¹

The effects of STN-DBS on autonomic symptoms are currently being investigated and, to date, have been considered as investigational. A summary of medical options, their adverse effects, and the level of evidence can be found in Table 5.

Psychiatric comorbidity in PD patients and its treatment

Impulse control disorders, dopamine dysregulation syndrome, and punding Possible long-term side-effects of dopaminergic treatment in PD are impulse control disorders, punding, or dopamine dysregulation syndrome. The latter describes craving for dopaminergic medication when medication effects are at its peak, but also other behavioral symptoms such as hypomania, hypersexuality and/or gambling, and dysphoria. In contrast, fatigue or apathy might occur towards the end of the dopaminergic effect.⁸²,⁸³ Therefore, therapy recommendations include the reduction of dopaminergic therapy, in particular the switch from DA to levodopa. Amantadine as an add-on to dopaminergic treatment might also reduce impulsivity and compulsiveness, although this has only been proven so far in a small number of patients.⁸⁴ Lastly, in the authors’ own experience, low dosage of an antipsychotic agent (eg, quetiapine 25–50 mg at night) also helps stabilizing such symptoms with only rare side effects, although no clinical trials are yet available in this context.⁸⁵

Medication-induced psychosis

Psychotic disorders are rare in untreated PD patients⁸⁵ but more common after initiation of dopaminergic medication.⁸⁶ Besides treatment with levodopa and/or DAs, further predisposing risk factors for psychosis in PD are older age,⁸⁷,⁸⁸ increasing severity of cognitive impairment or dementia,⁸⁸,⁹⁰ disease severity,⁸⁸,⁹¹ and polypharmacy.⁹⁶

Psychosis occurs in two different manifestations: (1) PD patients experiencing visual perceptual changes or visual hallucinations only (although other forms of hallucination can also occur);⁹⁰ and (2) patients classically presenting dementia and experiencing complex psychotic symptoms, including both hallucinations and systematized persecutory delusions in the context of dementia.⁹² Dementia with Lewy bodies requires special mention as the cognitive decline progresses faster than in classical PD, and these patients tend to develop psychosis with delusions.⁹¹ Compared to the first group, patients suffering from dementia with Lewy bodies and patients with complex psychotic symptoms typically do not have insight into their psychosis. However, once psychotic symptoms emerge, therapy for psychosis does not differ significantly between both groups.

General therapeutic recommendations include the switch to PD treatments with a smaller potential to enhance psychosis and the search for its underlying reasons. It is important to keep in mind that metabolic disorders or infection can be responsible – but also easily manageable – reasons for acute psychotic symptoms. Therefore, they should be ruled out before initiation of antipsychotic therapy. This is particularly important as classical neuroleptics have a substantial antidopaminergic effect, making their use in PD complicated.

Nevertheless, antipsychotics and especially atypical ones can and should be utilized. For example, clozapine has proven efficacious in several studies against psychotic symptoms.⁷¹,⁹³ Its risk of potential life-threatening agranulocytosis makes regular follow-up inevitable. Alternatives with a better risk profile are therefore highly desirable. As such, quetiapine has emerged during the last few decades, showing good effects in some small-sized and short-term studies⁵⁵,⁹⁴,⁹⁵ in one study demonstrating similar benefits to those observed with clozapine.⁹⁶ However, there are also results showing
### Table 5: Treatment of autonomic dysfunctions in Parkinson’s disease patients

| Symptom/ substance                      | Mechanism                                                                                      | Dosage                        | Adverse events                                                                                      | Special monitoring | Evidence                                      |
|-----------------------------------------|------------------------------------------------------------------------------------------------|-------------------------------|---------------------------------------------------------------------------------------------------|--------------------|-----------------------------------------------|
| Orthostatic hypotension                 |                                                                                                 |                               |                                                                                                   | None required      | Possibly effective, but insufficient evidence for improvement due to methodological concerns |
|                                        | Fludrocortisone                                                                              | 0.05–0.3 mg/day                | Edema, water and sodium retention, insomnia, fatigue                                            | None required      | Possibly effective, but insufficient evidence for improvement due to methodological concerns |
|                                        | Domperidone                                                                                  | 3 × 10–20 mg/day               | Extrapyramidal symptoms, increased levels of prolactin leading to gynecomastia or galactorrhea | None required      | Possibly effective, but insufficient evidence for improvement due to methodological concerns |
| Urinary disturbance                     |                                                                                                 |                               |                                                                                                   | None required      | Possibly useful for treatment of urge incontinence but insufficient evidence |
|                                        | Trospium chloride                                                                            | 2–3 × 10–20 mg/day             | Dry mouth, constipation, nausea, diarrhea, eye or eyesight problems, cognitive impairment          | None required      | Possibly useful for treatment of urge incontinence but insufficient evidence |
|                                        | Oxybutynin                                                                                     | 2 × 2.5–5 mg/day               | Dry mouth, constipation, nausea, diarrhea, eye or eyesight problems, cognitive impairment          | None required      | Possibly useful for treatment of urge incontinence but insufficient evidence |
| Gastrointestinal motility problems      | Macrogol                                                                                      | 1–3 × 125 mL/day               | Abdominal pain, diarrhea                                                                          | None required      | Likely efficacious for treatment of chronic constipation |
|                                        | Domperidone                                                                                   | 3 × 10–20 mg/day               | Increased levels of prolactin leading to gynecomastia or galactorrhea, extrapyramidal symptoms     | None required      | Possibly useful for treatment of nausea/vomiting due to medication |
| Erectile dysfunction                     | Sildenafil                                                                                     | Sildenafil: 50 mg 1 hour before sexual activity. | Headache, flushing, dyspepsia, nasal congestion, myocardial infarction                           | None required      | Sildenafil is possibly useful for treatment of erectile dysfunction in PD |
|                                        | Tadalafil                                                                                     | Tadalafil: 10 mg 0.5–12 hours before sexual activity. |                                                                                                   |                    |                                               |
|                                        | Vardenafil                                                                                     | Vardenafil: 10 mg 0.5–1 hour before sexual activity. |                                                                                                   |                    |                                               |
|                                         |                                                                                                 |                               |                                                                                                   |                    |                                               |

**Abbreviations:** cGMP, cyclic guanosine monophosphate; PD, Parkinson’s disease.

---

no superiority to placebo. Hence, a recommendation is not possible currently and awaits further research. Finally, in special cases, possible agents are also cholinesterase inhibitors, which have demonstrated a decrease in hallucinations in patients suffering from dementia with Lewy bodies.

**Antidementive therapy in PD**

Cognitive decline is one of the most disabling symptoms in PD during the later stages and, as such, an important symptom to be treated. One of the underlying reasons might be the spread of neurodegeneration with cortical cholinergic deficiency. Thus, anticholinergics and tricyclic antidepressants (TCAs) should be replaced where possible as they deteriorate cognitive performance. Available therapies for treating dementia are scarce and only two groups of medications are available. First, cholinesterase inhibitors – especially rivastigmine, which have demonstrated efficacy in the treatment of cognitive impairment in PD. Other cholinesterase inhibitors were either not tested systematically (eg, galantamine) or showed conflicting results (eg, donepezil) and are therefore not recommended. Also, it needs to be kept in mind that all cholinesterase inhibitors...
should be monitored cautiously as a worsening of tremor, autonomic dysfunction, and the induction of psychosis are possible. The second structure to be targeted is N-methyl-D-aspartic acid receptor. Memantine as an N-methyl-D-aspartic acid antagonist appears to have a modest improvement in cognitive performance in PD patients\textsuperscript{101,102} and might be considered for improving cognition and general clinical impression.

Antidepressive therapy in PD

Depression is a common manifestation either as preclinical symptom\textsuperscript{103} or during the course of PD. Prevalence ranges between 2.7\% and 90\%, depending on diagnosis criteria and the types of depressive disorders included. In any case, many PD patients consider QOL most impaired by their decreased emotional state.\textsuperscript{104} Yet, depression in PD is independent of motor symptoms\textsuperscript{105,106} and should therefore be addressed separately; nevertheless, sufficient dopaminergic therapy needs to be ensured due to the importance of dopamine in the limbic system.\textsuperscript{107} One possible way of addressing both problems might be pramipexole, as it helps with motor symptoms and has showed an antidepressant effect in experimental animal models\textsuperscript{108,109} as well as in clinical routine.\textsuperscript{110} For the clinical efficacy of actual antidepressants, there are only sparse high-standard studies. TCAs such as desipramine and nortriptyline have proven effective in improving depressive mood.\textsuperscript{65} However, their use is restricted in many cases by side effects such as cognitive impairment, autonomic dysfunction, and orthostatic dysregulation. Therefore, TCAs should be used carefully, particularly in elderly PD patients. Alternatively, treatment with modern antidepressants has also provided good results in clinical routine. Again, systematic studies are lacking and side effects include a possible interaction with MAO\textsubscript{n} inhibitors, leading to a serotonin syndrome. Nevertheless, these are very unlikely risks compared to those listed in older antidepressants (eg, TCA). Lastly, modern antidepressants such as atomoxetine could not show any beneficial effect on depression in PD patients and should therefore not be considered. Drugs such as omega-3 or interventions with transcranial magnetic stimulation have to be regarded, to date, experimental.\textsuperscript{65} In summary, although high-standard studies are missing, the authors’ would rather use modern antidepressants such as selective serotonin reuptake inhibitors to treat depression and/or, whenever possible, switch to pramipexole.

Finally, it should be emphasized that the basis of every antidepressant therapy should be an introduction to educational programs. These programs should be considered even in early stages of PD without heavy motor impairments and should, in particular, include the improvement of coping strategies regarding PD symptoms.

A summary of available pharmaceutical options against psychiatric comorbidities in PD can be found in Table 6.

Other therapeutic options in PD

Pump therapy in PD

Motor fluctuations and/or dyskinesias range among the major concerns in the management of advanced PD, as stated above. An underlying mechanism might be fluctuating plasmatic dopamine concentrations with oral intake; therefore, two different forms of continuous nonoral applications have been developed and tested recently: the apomorphine pump and the levodopa/carbidopa intestinal gel (LCIG) pump.

General indications for apomorphine infusion and LCIG (but also DBS) in PD are quite similar: patients with significant effect on dopaminergic medication and pronounced motor fluctuations not responding to classical pharmacological therapy. Contraindications differ significantly between DBS and pump therapies; older patients and significant psychiatric or cognitive problems are generally considered as contraindications for DBS but with regular follow-up and monitoring are not necessarily contraindications for infusional treatments and LCIG in particular.\textsuperscript{111}

LCIG

Intestinal infusion of LCIG is an efficacious way of treating motor symptoms, as it has the same mechanisms of action as oral levodopa administration. Therefore, LCIG is infused into the proximal jejunum by means of a portable pump through a percutaneous endoscopic gastrostomy tube,\textsuperscript{111,112} although temporary application via nasoduodenal for testing of clinical response is also possible. Besides the efficacy in motor symptoms, nonmotor symptoms as well as QOL seem to be ameliorated.\textsuperscript{113} However, results have to be regarded carefully, since many of the available data originate from open-label and/or observational studies. In the authors’ opinion, this method is especially suited for older patients with late sequelae of levodopa therapy such as motor complications and for patients with a high risk of hallucinations.

Apomorphine pump

Apomorphine is a potent DA showing good efficacy for treating motor symptoms in PD. It is characterized by reaching its plasmatic maximum in less than 10 minutes after subcutaneous application. Therefore, apomorphine rapidly
### Treatment of concomitant psychiatric symptoms in Parkinson’s disease patients

| Symptom/ substance | Mechanism | Dosage | Adverse events | Special monitoring | Evidence |
|--------------------|-----------|--------|----------------|-------------------|----------|
| **Impulse control disorders, punding, dopamine dysregulation syndrome** | | | | | |
| Amantadine | Unclear, possibly the interaction of several pharmacological mechanisms | 2–3 × 100–200 mg/day | Reversible corneal edema, nervousness, anxiety, agitation, insomnia, exacerbations of preexisting seizure disorders and psychiatric symptoms | None required | Investigational as there is only a small study looking at medication-related impulse dyscontrol and pathologic gambling and only for a few weeks |
| Quetiapine | Acts as antagonists for many neurotransmitters (at dopamine, serotonin, histamine, and adrenergic receptors) | 25–75 mg at night | Somnolence, fatigue, dry mouth, dizziness, constipation, weight gain | None required | Personal experience without any studies available |
| **Psychosis in PD** | | | | | |
| Clozapine | Antagonist at the 5-HT2A, dopamine, and several other receptors | 12.5–50 mg/day | Agranulocytosis, cardiac toxicity, hyperactivation, fatigue, weight gain | Regular blood testing is mandatory and regular echocardiograms can be performed | Good evidence for efficacy in treatment of psychosis in PD[95–97,99] |
| Quetiapine | Acts as antagonists for many neurotransmitters (at dopamine, serotonin, histamine, and adrenergic receptors) | 25–75 mg at night | Somnolence, fatigue, dry mouth, dizziness, constipation, weight gain | None required | Possibly useful for treatment of psychosis in PD, but insufficient evidence due to methodological concerns |
| Donepezil | Acetylcholinesterase inhibitor | 5–10 mg | Nausea, diarrhea, abdominal pain, transient increase of tremor severity | None required | Possibly useful for treatment of psychosis in patients suffering from Lewy body dementia[99] |
| **Antidementive therapy in PD** | | | | | |
| Rivastigmine | Acetylcholinesterase inhibitor | 4.6–9.2 mg/day | Diarrhea, bradycardia, nausea, abdominal pain, transient increase of tremor severity | None required | Efficacious in the treatment of dementia in PD[101–103] |
| Memantine | NMDA receptor antagonist | 20 mg/day | Confusion, drowsiness, headache, agitation and/or hallucinations | None required | Possibly useful but contradictory results in small studies[45,100–102,110] |
| **Antidepressive therapy in PD** | | | | | |
| Pramipexole | Partial or full dopamine receptor agonist with different affinity to the distinct dopamine receptor subtypes[97] | 3 × 0.35–0.7 mg/day | Fatigue, nausea, constipation and edema, somnolence | Psychiatric side effects should be taken into consideration and monitored cautiously | Efficacious for the treatment of depressive symptoms in PD [41,171,172] |
| Desipramine | Norepinephrine and (to a lesser extent) serotonin reuptake inhibition | | Cardiac arrhythmicity, dry mouth, constipation, orthostatic dysregulation, mild blurred vision | Cardiac monitoring | Likely efficacious for the treatment of depression in PD[173] |
| Nortriptyline | Norepinephrine and (to a lesser extent) serotonin reuptake inhibition | 75–150 mg/day | Dry mouth, constipation, orthostatic dysregulation, mild blurred vision | None required | Nortriptyline possibly improves depression in PD patients, but insufficient evidence up to now for the treatment of depression in PD[45] |
| SSRIs | Selectively inhibit the serotonin reuptake | Different agents available | Apathy, anhedonia, nausea/vomiting, headache, diarrhea, weight gain | Possibility of inducing serotonin syndrome effect together with MAO-B inhibitors, for example, is feasible (although improbable) | No clear evidence yet to be found, but possibly clinically useful as SSRIs have a better safety profile compared to TCAs |

**Abbreviations:** 5-HT2A, 5-hydroxytryptamine receptor 2A; MAO-B, monoamine oxidase B; NMDA, N-Methyl-D-aspartic acid; PD, Parkinson’s disease; SSRi, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.
increases the duration of “on” phases and is effectively applicable to patients with motor fluctuations.\textsuperscript{114,115} Two methods are available: (1) subcutaneous apomorphine injections “on demand;” or (2) continuous subcutaneous injection by means of a pump. Both forms might cause side effects, the most frequent being nausea and vomiting. This can be addressed effectively by administering domperidone several days before the first application. Another important problem to be considered is the emergence of cutaneous nodules in almost 100% of the cases, leading not only to a cosmetic problem but also to worse resorption. As a consequence, a regular change of the injection side is unavoidable. Eventually, psychiatric effects from hallucinations to acute psychotic syndrome may occur particularly in patients with preexisting psychiatric conditions. Taken together, and due to the common comorbidity of motor fluctuations and psychiatric symptoms in later stages of PD, the use of apomorphine is hence restricted. For patients suffering from motor complications, apomorphine is, nevertheless, a good choice providing satisfactory immediate and long-term results.\textsuperscript{116}

**Functional surgery in PD**

In recent years, DBS has emerged as efficacious therapy for different medically refractory neurological symptoms using current pulses in different target areas. Origins of DBS go back to lesional/ablative approaches under which improvement of both tremor (eg, after thalamotomy) and akinesia/rigidity (eg, via pallidotomy) could be achieved. The mechanisms of action remain elusive but different approaches are discussed: (1) depolarizing blockade, (2) synaptic inhibition, (3) synaptic depression, and (4) simulation-induced disruption of pathological network activity.\textsuperscript{117} From a clinician’s point of view, in contrast, additional questions need to be answered, as there are different areas to be targeted and these involve distinct “pros” and “cons.” Therefore, side effects or the best moment for surgery are nowadays subject of intensive investigation.

**Target points and specific side effects**

There are no guidelines for the target structure for DBS in PD. Different arguments can be used for an appropriate and individual clinical decision.

**STN**

Today, STN is considered the most effective for DBS in PD as it improves all cardinal symptoms. Also, it provides better long-term results in motor outcome compared to the classic target point – the internal globus pallidus (GPi). In addition, the STN shows less decay of motor efficacy in long-term studies.\textsuperscript{118,119} From a short-term perspective, however, there are side effects due to the small size of the STN and the stimulation of adjacent structures as well as functional loops interconnected within the STN. Limbic and affective loops in particular seem to be afflicted by stimulation, leading to postoperative dysphoria and hypomania\textsuperscript{120} and a higher risk of suicide.\textsuperscript{121} In addition, cognitive decline has been attributed to STN-DBS, particularly in patients with advanced age, higher dopaminergic medications, and higher axial subscores of the Unified PD Rating Scale.\textsuperscript{122} The reasons are unclear, although due to the heterogeneous results, electrode localization and/or the trajectory through the frontal lobe has been speculated playing a role in cognitive decline.\textsuperscript{123} As a result, STN is indicated as an effective target when younger patients suffer from severe motor complications, such as dyskinesias or fluctuations.

**GPi**

The original operative PD treatment, the GPi has lost importance – compared to STN-DBS – due to its disadvantages. This was due to worse long-term results,\textsuperscript{118,119} higher energy consumption, and the lack of possibility in reducing dopaminergic medications drastically with GPi-DBS. However, during the last few years, GPi-DBS is regaining importance for several reasons. First, GPi is easier to target, since it is a bigger structure than STN. Secondly, patients operated on in the GPi are less prone to develop psychiatric and cognitive implications. And finally, GPi-DBS appears to be more efficient in treating some of the nonmotor symptoms in PD. Also, worse long-term results could not be replicated in other studies.\textsuperscript{124} Therefore, GPi will be possibly targeted in the future more frequently and should be taken into account in elderly patients who might develop psychiatric or cognitive impairments.

**Ventral posterolateral nucleus of the thalamus (VLp)**

The thalamus was the traditional target for stereotactic tremor surgery as ablative procedures in the VLp\textsuperscript{*} showed good efficacy, and stimulation has also consistently shown long-lasting therapy of contralateral tremor. However, the structure has lost its importance in PD since other cardinal symptoms are not modified to the same extent. Therefore,\textsuperscript{125}

\textsuperscript{*The VLp partially corresponds to Hassler’s ventral intermediate nucleus (Vim).\textsuperscript{126} To maintain a uniform nomenclature, the Vim will be referred to as VLp.
VLp-DBS should only be considered in patients suffering from severe tremor and when other options appear less practicable. Advantages are mainly the fewer aforementioned side effects during VLp-DBS compared to equally effective target points such as STN or GPi. Possible side effects of this target are on the one hand a stimulation of structures in the vicinity of the VLp with resulting dystarthism, paresthesias, or gait disturbances and on the other hand mild executive deficits (e.g., in verbal fluency). Therefore exact planning and meticulous intraoperative testing of tremor-dominant and elderly patients is required in order to stimulate segregated motor loops.

Pedunculopontine nucleus
This brain area was introduced as an additional DBS target, with the purpose of ameliorating axial symptoms responding in an unsatisfactory way to DBS of other structures or medical treatment. So far, it has been practiced as an add-on to STN-DBS, providing controversial results. Therefore, no recommendation on DBS in the pedunculopontine nucleus can be made at this point.

General considerations
The safety and efficacy of DBS in PD has been proven not least because of the clinical experience with thousands of patients. However, there are several different open and general questions concerning DBS. For instance, there is still an open debate on how many targets should be operated on. As PD is a lateral disease, some centers conduct unilateral electrode implantation as studies have demonstrated unilateral DBS being associated with better QOL and reduced surgery time. On the other hand, PD is a progressive disease which spreads to both sides, therefore making a second electrode in later stages necessary. This, however, leads to duplicated operation risks and therefore higher economic expenses for health care systems. Concerning medical issues, in contrast, there are no short-term differences for motor outcome between unilateral and bilateral implantation. All in all, and subject to limited exceptions, the authors therefore plead in favor of a bilateral implantation.

However, having determined the amount of targets leads to the question as to when is the best moment for surgery. Nowadays, DBS is only practiced in patients suffering from medically refractory motor restraints. However, there is growing evidence that although not neuroprotective, DBS leads to a better QOL. Therefore, it is conceivable that early stimulation has great repercussions on QOL. Preliminary results of an international randomized and multicenter study (Controlled Trial of Deep Brain Stimulation in Early Patients With Parkinson’s Disease; EARLYSTIM study) have been recently presented and the final results are expected in the near future. Nevertheless, the risks of precipitated electrode implantation should be pointed out. First, there is a disproportional risk of confounding other or atypical parkinsonian syndromes in the first years of symptoms. And secondly, it should be kept in mind that patients can continue functioning well for years with only medical treatment without being exposed to the risks of surgery.

Regarding these open questions, the decision for surgery should be made by an interdisciplinary team. In the authors’ center, neurologists, neurosurgeons, psychiatrists, and other specialists – depending on the underlying problems (e.g., physical therapist, occupational therapist, speech therapist, social worker) – are involved in the decision. In addition, past medical history, current comorbidities, imaging studies, and the Unified PD Rating Scale in the “on” and “off” condition should be carefully considered when it comes to decide whether or not to operate, or which structure to target in PD patients. The authors believe that this increases the quality and the outcomes of this procedure, and therefore patients obtain satisfying results.

Summary
In summary, as the possibilities have increased dramatically in the last decades, first attempts to alleviate motor symptoms with just levodopa have been abandoned. Although still considered the most effective drug, the awareness of possible long-term risks has led to more sophisticated regimens with additional agents and additional therapeutic options such as infusional therapies or DBS. For a practical approach, the current German guidelines for PD therapy are referred to (Figure 1).

However, it needs to be remembered that such schemes are not suited for tailoring the best individual medication. The reason for this is that they focus on the treatment of the cardinal motor symptoms and do not include other therapeutic targets. Yet, the awareness of additional restraints and nonmotor symptoms is important, as they are often perceived as highly impairing. It therefore results in an even more complex situation for physicians, as every patient needs their risk profile and concomitant diseases considered.

Finally, as current therapies improve QOL and motor restraints in early stages of the disease, physicians face the problem of additional problems and long-term side effects in later stages. In many cases, these circumstances are especially
German guidelines for treatment of PD 2012

Biological age

Mild motor disability
- Rasagline (selegiline)
- Dopamine-agonist (DA)
- L-dopa
- L-dopa plus COMT-I
- Amantadine

Moderate to severe motor disability
- L-dopa plus COMT-I
- Plus DA
- Rasagline (selegiline)

Treatment of advanced PD
- Consideration in individual cases: invasive pump therapy or DBS
- • invasive pump therapy (apomorphine/duodopa)
- • DBS

Figure 1 German guidelines for treatment of PD 2012.

Abbreviations: COMT-I, catechol-O-methyltransferase-inhibitor; DA, dopamine agonist; DBS, deep brain stimulation; PD, Parkinson’s disease.

challenging as there is currently no effective response. Therefore, further investigation is highly desirable in order to develop even better therapies which allow the modification of the neurodegenerative processes and provide solutions for the existing additional motor and nonmotor symptoms in PD patients.

Disclosure
The authors report no conflicts of interest in this work.

References

1. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197–211.

2. Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson’s-diseased striatum. Synapse. 1991;9(1):43–49.

3. Niznik HB, Fogel EF, Fassos FF, Seeman P. The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus. J Neurochem. 1991;56(1):192–198.

4. Eggers C, Pedrosa DJ, Kahraman D, et al. Parkinson subtypes progress differently in clinical course and imaging pattern. PLoS One. 2012;7(10):e46813.

5. Rajput AH, Voll A, Rajput ML, Robinson CA, Rajput A. Course in Parkinson disease subtypes: a 39-year clinicopathologic study. Neurology. 2009;73(3):206–212.

6. Ashburn A, Fazakarley L, Ballinger C, Pickering R, McLellan LD, Fittin C. A randomised controlled trial of a home based exercise programme to reduce the risk of falling among people with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2007;78(7):678–684.

7. Cakir BD, Saracoglu M, Genc H, Erdem HR, Inan L. The effects of incremental speed-dependent treadmill training on postural instability and fear of falling in Parkinson’s disease. Clin Rehabil. 2007;21(8):698–705.

8. Ebersbach G, Ebersbach A, Edler D, et al. Comparing exercise in Parkinson’s disease – the Berlin LSVT®BIG study. Mov Disord. 2010;25(12):1902–1908.

9. Ellis T, de Goede CJ, Feldman RG, Wolters EC, Kwakkel G, Wagenaar RC. Efficacy of a physical therapy program in patients with Parkinson’s disease: a randomized controlled trial. Arch Phys Med Rehabil. 2005;86(4):626–632.

10. Morris ME, Fansek R, Kirkwood B. A randomized controlled trial of movement strategies compared with exercise for people with Parkinson’s disease. Mov Disord. 2009;24(1):64–71.

11. Barbe MT, Cepuran F, Amarell M, Schoenau E, Timmermann L. Long-term effect of robot-assisted treadmill walking reduces freezing of gait in Parkinson’s disease patients: a pilot study. J Neurol. 2013;260(1):296–298.

12. Tomlinson CL, Patel S, Meek C, et al. Physiotherapy versus placebo or no intervention in Parkinson’s disease. Cochrane Database Syst Rev. 2012;7:CD002817.

13. Chrisp R, Mammen GJ, Sorkin EM. Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson’s disease. Drugs Aging. 1991;1(3):228–248.

14. Youdim MB, Bar Am O, Yogev-Falach M, et al. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res. 2005;79(1–2):172–179.

15. Zou L, Jankovic J, Rowe DB, Xie W, Appel SH, Le W. Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sci. 1999;64(15):1275–1285.

16. Beal MF, Matthews RT, Tielman A, Shults CW. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3, tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res. 1998;783(1):109–114.

17. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. Mov Disord. 2009;24(1):64–71.

18. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in Parkinson’s disease. J Neurosci. 2007;27(36):9682–9689.

19. Schapira AH, Albrecht S, Barone P, et al. Rationale for delayed-start study of rasagiline in early Parkinson’s disease. Mov Disord. 2010;25(11):1627–1632.
20. Hart RG, Pearce LA, Ravina BM, Yaltho TC, Marler JR. Neuroprotection trials in Parkinson's disease: systematic review. Mov Disord. 2009;24(5):647–654.

21. Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord. 2005;20(5):523–539.

22. Adler CH, Singer C, O'Brien C, et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch Neurol. 1998;55(8):1089–1095.

23. Deane KH, Spieker S, Clarke CE. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev. 2004;(4):CD004554.

24. Kurth MC, Adler CH, Hilaire MS, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology. 1997;48(1):81–87.

25. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351(24):2498–2508.

26. Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI. Adding a dopamine agonist to preexisting levodopa therapy vs levodopa therapy alone in advanced Parkinson's disease: a meta-analysis. Int J Clin Pract. 2009;63(4):613–623.

27. Reinhart K. Efficacy of combining levodopa with entacapone in patients with Parkinson disease experiencing motor fluctuations: a multicenter, double-blind, randomized trial. Mov Disord. 2008;23(Suppl 2):S475–S481.

28. Fox SH, Katschenschlager R, Lim SY, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2011;26(Suppl 3):S2–S41.

29. Moller JC, Oertel WH, Koster J, Pezzoli G, Provinciali L. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord. 2005;20(5):602–610.

30. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61(7):1044–1053.

31. Hauser RA, Rascol O, Korczyn AD, et al. Ten-year follow-up of Parkinson's disease: 2001 to 2004. Mov Disord. 2007;22(16):2409–2417.

32. Olanow CW, Watkins PB. Tolcapone: an efficacy and safety review (2007). Clin Neuropharmacol. 2007;30(5):287–294.

33. Reichmann H, Boas J, Macmahon D, Myllylä V, Hakala A, Reimikainen K. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurol Scand. 2005;111(1):21–28.

34. Snow BJ, Macdonald L, Mcauley D, Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol. 2000;23(2):82–85.

35. Luginger E, Wenning GK, Bosch S, Poewe W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord. 2000;15(9):873–878.

36. Hauser RA, Cantillon M, Pourcher E, et al. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol. 2011;10(3):221–229.

37. Hodgson RA, Bedard PJ, Varty GB, et al. Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders. Exp Neurol. 2010;225(2):384–390.

38. Postuma RB, Lang AE, Munhoz RP, et al. Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology. 2012;79(7):651–658.

39. Olanow CW, Obeso JA, Stocchi F. Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease. Nat Clin Pract Neurol. 2006;2(7):382–392.

40. Ondo WG, Sethi KD, Kricorian G. Selegiline orally disintegrating tablets in patients with Parkinson disease and “wearing off” symptoms. Clin Neuropharmacol. 2007;30(5):295–300.

41. Crosby N, Deane KH, Clarke CE. Amantadine in Parkinson's disease. Cochrane Database Syst Rev. 2003;(1):CD003468.

42. Pedrosa DJ, Reck C, Florin E, et al. Essential tremor and tremor in Parkinson's disease are associated with distinct “tremor clusters” in the ventral thalamus. Exp Neurol. 2012;237(2):435–443.

43. Helmich RC, Janssen MJ, Oyen WJ, Bloem BR, Toni I. Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor. Ann Neurol. 2011;69(2):269–281.

44. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med. 1999;340(10):757–763.

45. Hariz MI, Krack P, Alesch F, et al. Multicentre European study of thalamic stimulation for parkinsonian tremor: a 6 year follow-up. J Neurol Neurosurg Psychiatry. 2008;79(6):694–699.

46. Pillon B, Dubois B, Bonnet AM, et al. Cognitive slowing in Parkinson's disease fails to respond to levodopa treatment: the 15-objects test. Neurology. 1989;39(6):762–768.

47. Levy G, Louis ED, Cote L, et al. Contribution of aging to the severity of different motor signs in Parkinson disease. Arch Neurol. 2005;62(3):467–472.

48. Rahman S, Griffin JH, Quinn NP, Jahanshahi M. The factors that induce or overcome freezing of gait in Parkinson’s disease. Behav Neurol. 2008;19(3):127–136.

49. Nieuwboer A, Kwakkel G, Rochester L, et al. Cueing training in the home improves gait-related mobility in Parkinson’s disease: the RESCUE trial. J Neurol Neurosurg Psychiatry. 2007;78(2):134–140.

50. Arias P, Cudeiro J. Effect of rhythmic auditory stimulation on gait in parkinsonian patients with and without freezing of gait. PLoS One. 2010;5(3):e9675.

51. Nieuwboer A, Baker K, Willems AM, et al. The short-term effects of different cueing modalities on turn speed in people with Parkinson's disease. Neurorehabil Neural Repair. 2009;23(8):831–836.

52. Nieuwboer A. Cueing for freezing of gait in patients with Parkinson’s disease: a rehabilitation perspective. Mov Disord. 2008;23(Suppl 2):S475–S481.

53. Allen NE, Canning CG, Sherrington C, et al. The effects of an exercise program on fall risk factors in people with Parkinson’s disease: a randomized controlled trial. Mov Disord. 2010;25(9):1217–1225.

54. Davis JT, Lyons KE, Palha R. Freezing of gait after bilateral subthalamic nucleus stimulation for Parkinson's disease. Neurology. 2008;70(16 Pt 2):1431–1437.

55. Jankovic J. Long-term study of pergolide in Parkinson’s disease. Neurology. 1985;35(3):296–299.

56. Garbuzova-Davis A, Davis JT, Lyons KE. Freezing of gait or overcome freezing of gait in Parkinson’s disease. Clin Neurol Neurosurg. 2004;106(5):461–466.

57. Moreau C, Defehvre L, Destee A, et al. STN-DBS frequency effects on freezing of gait in advanced Parkinson disease. Neurology. 2008;71(2):80–84.

58. Ferraye MU, Debu B, Fraix V, et al. Effects of subthalamic nucleus stimulation and levodopa on freezing of gait in Parkinson disease. Neurology. 2008;70(16 Pt 2):1431–1437.

59. Clouet-Mourot C, Brule M, Simonet C, et al. Functional neuroanatomy of the pallidum in Parkinson's disease: DTI analysis. Neuroimage. 2009;47(1):204–212.

60. Parkinson Study Group. Randomized clinical trial of rasagiline with levodopa in the management of levodopa-induced dyskinesia in Parkinson's disease: the RDaSH study. Arch Neurol. 2007;64(1):1–8.

61. Jankovic J. Parkinsonism, head drop and other bent spine syndromes. Heterogeneous etiology and pathogenesis of parkinsonian deformities. Mov Disord. 2010;25(5):527–528.

62. Claassen DO, Josephs KA, Ahlsgog JE, Silber MH, Tippmann-Peikert M, Boeve BF. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology. 2010;75(6):494–499.
64. Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. *Brain*. 2000;123( Pt 2):331–339.

65. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. *Mov Disord*. 2011;26(Suppl 3):S42–S80.

66. Aurora RN, Kristo DA, Bista SR, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults – an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. *Sleep*. 2012;35(8):1039–1062.

67. Oertel W, Trenkwalder C, Benes H, et al. Long-term safety and efficacy of subthalamic stimulation on sleep in Parkinson’s disease. *Neurosurg Psychiatry*. 2010;68(3):400–404.

68. Arnulf I, Bejiani BP, Garma L, et al. Improvement of sleep architecture in PD with subthalamic nucleus stimulation. *Neurology*. 2000;55(11):1732–1734.

69. Irando A, Valideorloa F, Santamaria J, Tolosa E, Rumia J. Sleep symptoms and polysomnographic architecture in advanced Parkinson’s disease after chronic bilateral subthalamic stimulation. *J Neurol Neurosurg Psychiatry*. 2002;72(5):661–664.

70. Monaca C, Orszancak J, Jacquesson JM, et al. Effects of bilateral subthalamic stimulation on sleep in Parkinson’s disease. *J Neurol*. 2004;251(2):214–218.

71. Kedia S, Moro E, Tagliati M, Lang AE, Kumar R. Emergence of restless legs syndrome during subthalamic stimulation for Parkinson disease. *Neurology*. 2004;63(12):2410–2412.

72. Arnulf I, Bejiani BP, Garma L, et al. Effect of low and high frequency thalamic stimulation on sleep in patients with Parkinson’s disease and essential tremor. *J Sleep Res*. 2000;9(1):55–62.

73. Larsen JP, Tandberg E. Sleep disorders in patients with Parkinson’s disease: epidemiology and management. *CNS Drugs*. 2001;15(4):267–275.

74. Wakabayashi K, Takahashi H, Okame T, Takeda S, Ikuta F. Lewy bodies in the visceral autonomic nervous system in Parkinson’s disease. *Adv Neurol*. 1993;60:609–612.

75. Lahmann H, Cortellini P, Hilt M, Mathias CJ, Struhal W, Tassinari M. EFNS guidelines on the diagnosis and management of orthostatic hypotension. *Eur J Neurol*. 2006;13(9):930–936.

76. Aranda B, Cramer P. Effects of apomorphine and L-dopa on the motor response to galantamine in Parkinson’s disease with dementia. *Clin Neuropharmacol*. 2002;25(1):1–7.

77. Restivo DA, Palmeri A, Marchese-Ragona R. Botulinum toxin for cricopharyngeal dysfunction in Parkinson’s disease. *N Engl J Med*. 2002;346(15):1174–1175.

78. El Sharkawi A, Ramig L, Logemann JA, et al. Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT): a pilot study. *J Neurol Neurosurg Psychiatry*. 2002;72(1):31–36.

79. Briganti A, Salonia A, Gallina A, et al. Drug insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction. *Nat Clin Pract Urol*. 2005;2(5):239–247.

80. Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson’s disease: reward systems gone awry? *Lancet Neurol*. 2003;2(10):595–604.

81. Evans AH, Lees AJ. Dopamine dysregulation syndrome in Parkinson’s disease. *Curr Opin Neurol*. 2004;17(4):393–398.

82. Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M. Pathological gambling in Parkinson disease is reduced by amantadine. *Ann Neurol*. 2010;68(3):400–404.

83. Cummings JL. Behavioral complications of drug treatment of Parkinson’s disease. *J Am Geriatr Soc*. 1991;39(7):708–716.

84. Henderson MJ, Mellers JDC. Psychosis in Parkinson’s disease: “between a rock and a hard place.” *Int Rev Psychiatry*. 2000;12(4):319–334.

85. Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson disease. *Arch Neurol*. 1996;53(12):1265–1268.

86. Pacchetti C, Manni R, Zangaglia R, et al. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson’s disease. *Mov Disord*. 2005;20(11):1439–1448.

87. Aarsland D, Larsen JP, Cummings JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. *Arch Neurol*. 1999;56(5):595–601.

88. Fenelon G, Mahieux F, Huser R, Ziegler M. Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. *Brain*. 2000;123(Pt 4):733–745.

89. Aarsland D, Ballard C, Larsen JP, McKeith I. A comparative study of psychotic symptoms in dementia with Lewy bodies and Parkinson’s disease with and without dementia. *Int J Geriatr Psychiatry*. 2001;16(5):528–536.

90. Marsh L, Williams JR, Rocco M, Grill S, Munro C, Dawson TM. Psychiatric comorbidities in patients with Parkinson disease and psychosis. *Neurology*. 2004;63(2):293–300.

91. Factor SA, Friedman JH, Lannon MC, Oakes D, Bourgeois K. Clozapine for the treatment of drug-induced psychosis in Parkinson’s disease: results of the 12 week open label extension in the PSYCLOPS trial. *Mov Disord*. 2001;16(1):135–139.

92. Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. *Clin Neuropharmacol*. 2004;27(4):153–156.

93. Ondo WG, Tintner R, Young KD, Lai D, Ringholz G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. *Mov Disord*. 2005;20(8):958–963.

94. Merims D, Balas M, Perez C, Shahtai H, Giladi N. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson’s disease psychosis. *Clin Neuropharmacol*. 2006;29(6):331–337.

95. Bergman I, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson’s disease. *Clin Neuropharmacol*. 2002;25(2):107–110.

96. Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson’s disease with dementia. *Int J Geriatr Psychiatry*. 2003;18(10):937–941.

97. Bohnen NI, Kaufer DJ, Ivanos L, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. *Arch Neurol*. 2003;60(12):1745–1748.

98. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. *N Engl J Med*. 2004;351(24):2509–2518.

99. Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. *Lancet Neurol*. 2009;8(7):613–618.

100. Leroi I, Overshott R, Byrne EJ, Daniel E, Burns A. Randomized controlled trial of memantine in dementia associated with Parkinson’s disease. *Mov Disord*. 2009;24(8):1217–1221.

101. Lemke MR, Fuchs G, Gemende I, et al. Depression and Parkinson’s disease. *J Neurol*. 2004;251(Suppl 6):VI/24–VI/27.

102. Global Parkinson’s Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson’s disease: results from an international survey. *Mov Disord*. 2002;17(1):60–67.

103. Kuopio AM, Marttila RJ, Helenius H, Toivonen M, Rinne UK. The quality of life in Parkinson’s disease. *Mov Disord*. 2000;15(2):216–223.
106. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry. 2000;69(3):308–312.

107. Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain. 2005;128(PT 6):1314–1322.

108. Maj J, Rogoz Z, Skuza G, Kolodzieczyk K. The behavioural effects of pramipexole, a novel dopamine receptor agonist. Eur J Pharmacol. 1999;324(1):31–37.

109. Willner P, Lappas S, Cheeta S, Muscat R. Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole. Psychopharmacology (Berl). 1994;115(4):454–462.

110. Lemke MR, Brecht HM, Koester J, Kraus PH, Reichmann H. Anhedonia, depression, and motor functioning in Parkinson’s disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci. 2005;17(2):214–220.

111. Antonini A, Tolosa E. Apomorphine and levodopa infusion therapies for advanced Parkinson’s disease: selection criteria and patient management. Expert Rev Neurother. 2009;9(6):859–867.

112. Lundqvist C. Continuous levodopa for advanced Parkinson’s disease. Neuropsychiatric Dis Treat. 2007;3(3):335–348.

113. Devos D. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson’s disease. Mov Disord. 2009;24(7):993–1000.

114. Poewe W, Kleeedorfer B, Wagner M, Bosch S, Schelosky L. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson’s disease. Long-term follow-up in 18 patients. Adv Neurol. 1993;60:656–659.

115. Stibe CM, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in parkinsonian off–on oscillations. Lancet. 1988;1(8582):403–406.

116. Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1990;53(2):96–101.

117. McIntyre CC, Savasta M, Kerkerian-Le Goif L, Vitek JI. Uncovering the mechanism(s) of action of deep brain stimulation: activation, inhibition, or both. Clin Neurophysiol. 2004;115(6):1239–1248.

118. Allert N, Lehrke R, Sturm V, Volkmer J. Secondary failure after ten years of pallidal neurostimulation in a patient with advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2010;117(3):349–351.

119. Volkmann J. Deep brain stimulation for the treatment of Parkinson’s disease. J Clin Neuropsychol. 2004;21(1):6–17.

120. Volkman J, Daniels C, Witt K. Neuropsychiatric effects of subthalamic neurostimulation in Parkinson disease. Nat Rev Neurol. 2010;6(9):487–498.

121. Voon V, Krack P, Lang AE, et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson’s disease. Brain. 2008;131(PT 10):2720–2728.

122. Daniels C, Krack P, Volkman J, et al. Risk factors for executive dysfunction after subthalamic nucleus stimulation in Parkinson’s disease. Mov Disord. 2010;25(11):1583–1589.

123. York MK, Wilde EA, Simpson R, Jankovic J. Relationship between neuropsychological outcome and DBS surgical trajectory and electrode location. J Neurol Sci. 2009;287(1–2):159–171.

124. Weaver FM, Follett KA, Stern M, et al. Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes. Neurology. 2012;79(1):55–65.

125. Krack P, Dostrovsky J, Ilinski Y, et al. Surgery of the motor thalamus: problems with the present nomenclatures. Mov Disord. 2002;17(Suppl 3):S2–S8.

126. Wojtczak I, Timmermann L, Jorgens S, et al. Frequency-dependent reciprocal modulation of verbal fluency and motor functions in subthalamic deep brain stimulation. Arch Neurol. 2006;63(9):1273–1276.

127. Mason A, Ilinski YA, Maldonado S, Kultas-Ilinski K. Thalamic terminal fields of individual axons from the ventral part of the dentate nucleus of the cerebellum in Macaca mulatta. J Comp Neurol. 2000;421(3):412–428.

128. Hamani C, Moro E, Lozano AM. The pedunculopontine nucleus as a target for deep brain stimulation. J Neural Transm. 2011;118(10):1461–1468.

129. Stefan F, Lozano AM, Peppe A, et al. Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson’s disease. Brain. 2007;130(PT 6):1596–1607.

130. Costa A, Carlesimo GA, Caltagirone C, et al. Effects of deep brain stimulation of the pedunculopontine area on working memory tasks in patients with Parkinson’s disease. Parkinsonism Relat Disord. 2010;16(1):64–67.

131. Stefan F, Pierantozzi M, Ceravolo R, Brusa L, Galati S, Stanzione P. Deep brain stimulation of pedunculopontine tegmental nucleus (PPTg) promotes cognitive and metabolic changes: a target-specific effect or response to a low-frequency pattern of stimulation? Clin EEG Neurosci. 2010;41(2):82–86.

132. Zahodne LB, Okun MS, Foote KD, et al. Greater improvement in quality of life following unilateral deep brain stimulation surgery in the globus pallidus as compared to the subthalamic nucleus. J Neurol. 2009;256(8):1321–1329.

133. Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease. N Engl J Med. 2010;362(22):2077–2081.

134. Okun MS, Fernandez JH, Wu SS, et al. Cognition and mood in Parkinson’s disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial. Ann Neurol. 2009;65(5):586–595.

135. Charles PD, Gill CE, Davis TL, Konrad PE, Benabid AL. Is deep brain stimulation neuroprotective if applied early in the course of PD? Nat Clin Pract Neurosurg. 2008;4(8):424–426.

136. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med. 2006;355(9):896–908.

137. Weaver F, Follett K, Hur K, Ippolito D, Stern M. Deep brain stimulation in Parkinson disease: a metaanalysis of patient outcomes. J Neurol. 2005;103(6):956–967.

138. Williams A, Gill S, Varma T, et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson’s disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol. 2010;9(6):581–591.

139. Rascol O, Dubois B, Caldas AC, Senn S, Del Signore S, Lees A. Early piribedil monotherapy of Parkinson’s disease: a planned seven-month report of the REGAIN study. Mov Disord. 2006;21(12):2110–2115.

140. Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol. 2009;66(5):563–570.

141. Barone P, Scarzella L, Marconi R, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel-group randomized study. J Neurol Neurosurg Psychiatry. 2006;253(5):601–607.

142. Palwa R, Lyons KE. Options in the treatment of motor fluctuations and dyskinesias in Parkinson’s disease: a brief review. Neurology. 2004;22(Suppl 3):S35–S52.

143. Wolf E, Seppi K, Katzenschlager R, et al. Long-term antidyskinetic efficacy of amantadine in Parkinson’s disease. Mov Disord. 2010;25(10):1357–1363.

144. Durif F, Debilly B, Galitzky M, et al. Clozapine improves anhedonia by the dopamine receptor agonist, pramipexole. Lancet. 1997;324(1):31–37.

145. Siassakos P, Gounis D, Halkos G, et al. Effect of pramipexole on levodopa-induced motor fluctuations in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1999;22(4):1077–1081.

146. Friedman JH, Koller WC, Lannon MC, Busenbark K, Swanson-Hyland E, Smith D. Benzotropine versus clozapine for the treatment of tremor in Parkinson’s disease. Neurology. 1997;48(4):1077–1081.

147. Anderson KN, Shneerson JM. Drug treatment of REM sleep behavior disorder: the use of drug therapies other than clonazepam. J Clin Sleep Med. 2009;5(3):235–239.
148. Stocchi F, Barbato L, Nordera G, Berardelli A, Ruggieri S. Sleep disorders in Parkinson's disease. J Neurol. 1998; 245(Suppl 1): S15–S18.

149. Ferini-Strambi L, Aarskog D, Partinen M, et al. Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial. Sleep Med. 2008;9(8):874–881.

150. Montagna P, Hornyak M, Ulfberg J, et al. Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood. Sleep Med. 2011;12(1):34–40.

151. Oertel WH, Stiasny-Kolster K, Bergholdt B, et al. Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study). Mov Disord. 2007;22(2):213–219.

152. Bogan RK, Fry JM, Schmidt MH, Carson SW, Ritchie SY. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc. 2006;81(1):17–27.

153. Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry. 2004;75(1):92–97.

154. Hening WA, Allen RP, Ono WG, et al. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. Mov Disord. 2010;25(11):1675–1683.

155. Oertel WH, Benes H, Garcia-Borreguero D, et al. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study. Sleep Med. 2010;11(9):848–856.

156. Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, Barrett RW. Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Sleep Med. 2009;72(5):439–446.

157. Kushida CA, Walters AS, Becker P, et al. A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep. 2009;32(2):159–168.

158. Lee DO, Ziman RB, Perkins AT, Roceta JS, Walters AS, Barrett RW. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med. 2011;7(3):282–292.

159. Walters AS, Ono WG, Kushida CA, et al. Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol. 2009;32(6):311–320.

160. Winkelmann JW, Bogan RK, Schmidt MH, Hudson JD, DeRoussset SE, Hill-Zabala CE. Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome. Mov Disord. 2011;26(11):2065–2072.

161. Hegl B, Paulus W, Clarenbach P, Trenkwalder C. Restless legs syndrome: diagnostic assessment and the advantages and risks of dopaminergic treatment. J Neurol. 2006;253(Suppl 4):IV22–IV28.

162. Garcia-Borreguero D, Larroso O, de la Llave Y, Verger K, Masromon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology. 2002;59(10):1573–1579.

163. Hampe S, Sauter C, Klösch G, Salduz B, Zeitlhofer J. Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. Neuropsychobiology. 2003;48(2):82–86.

164. Schoffer KL, Henderson RD, O’Maley K, O’Sullivan JD. Nonpharmacological treatment, fludrocortisone, and dopaminede for orthostatic hypotension in Parkinson’s disease. Mov Disord. 2007;22(11):1543–1549.

165. Zangaglia R, Martignoni E, Glorioso M, et al. Macrogol for the treatment of constipation in Parkinson’s disease. A randomized placebo-controlled study. Mov Disord. 2007;22(9):1239–1244.

166. Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson’s disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2001;71(3):371–374.

167. Fernandez HH, Okun MS, Rodriguez RL, et al. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysonomography study. Int J Neurosci. 2009;119(12):2196–2205.

168. Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord. 2007;22(3):313–318.

169. Shotbolt P, Samuel M, David A. Quetiapine in the treatment of psychosis in Parkinson’s disease. Ther Adv Neurol Disord. 2010;3(6):339–350.

170. Emre M, Tolsali M, Bonuccelli U, et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969–977.

171. Barone P, Poeoe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(6):573–580.

172. Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomised study. Eur J Neurol. 2003;10(4):399–406.

173. Devis D, Dujardin K, Poirat I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2008;23(6):850–857.

174. Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology. 2009;72(10):886–892.

175. Eggert K, Oertel WH, Reichmann H et al. Parkinson-Syndrome: Diagnostik und Therapie. In: “Leitlinien für Diagnostik und Therapie in der Neurologie”, Diener HC, Weimar C (ed). Leitlinien für Diagnostik und Therapie. In: “Leitlinien für Diagnostik und Therapie in der Neurologie”. Stuttgart: Thieme 2008:339–350.

176. Schuepbach WM, Rau J, Knudsen K, et al. EARLYSTIM Study Group. Neurostimulation for Parkinson’s disease with early motor complications. N Engl J Med. 2013;Feb 14;368(7):610–622. doi: 10.1056/NEJMoa1205158. PubMed PMID: 23406026.